Published :
Tables : 51
Figures : 44
Category : Healthcare
No. of Pages : 223
Report Code : HC-1218
Cardiac Biomarker Diagnostic Kits Market is poised to value USD 2549.71 million by 2028 end at a CAGR of 5.1% during the forecast period 2022 to 2028. Factors such as increasing geriatric population and increasing cases of cardiovascular diseases are increasing the cardiac biomarker diagnostic kits market size. Current clinical trials for identification of novel cardiac biomarkers coupled with increasing fund from public-private organizations for research and development is also expanding the market. The market is bifurcated into by type, by product, by disease, by type of testing and by region. The troponin I and T segment are expected to show notable cardiac biomarker diagnostic kits market growth owing to its high sensitivity, rapid prediction of outcomes and high specificity. It also offers longer elevation time. All these benefits have resulted in demand for troponin I and T, thus proliferating the market. Based on product, reagents and kits are expected to dominate the growth of the market. Increasing cases of cardiovascular diseases and the availability of multiple reagents ad kits is driving the growth of the market. In addition, the continuous launch of reliable, faster and new reagents and kits increasing the cardiac biomarker diagnostic kits size. On the basis of the type of testing, point-of-care testing is expected to control the growth of the market. Point-of-care testing offers various benefits such as enhanced user and patient experience, reduced length of stay and better turnaround times. All these benefits have resulted in rising point-of-care testing procedures. Technological advancements have led in much faster, advances and easy to use devices, thus resulting in expansion of the market. In terms of disease, myocardial infarction segment is expected to control the growth of the market. The increasing number of patients required for the diagnosis of acute myocardial infarction remains the major factor boosting the growth of the market. In terms of region, North America is the global front runner of the market. The rise in geriatric population coupled with presence of prominent players is bolstering the market in the region. The increasing incidence of cardiovascular disease coupled with rising adoption of point-of-care diagnostic is expected to accelerate the growth of the market in the region. Prominent players of the market are BioMerieux SA, Guangzhou Wondfo Biotech Co., Ltd, Danaher Corporation, Siemens AG, Abbott Laboratories, Alere, Inc., LSI Medience Corporation, Randox laboratories, and Ortho Clinical Diagnostics. Cardiac Biomarker Diagnostic Kits Market Segmentation: By Product Reagents and Kits Instruments Chemiluminescence Immunofluorescence Elisa Immunochromatography By Type Troponin I and T CK-MB Bnp Or Nt-Probnp Myoglobin Hscrp Other Biomarkers By Type of Testing Laboratory Testing Point-Of-Care Testing By Disease Myocardial Infarction Congestive Heart Failure By Region North America Europe Asia Pacific Latin America Rest of the World FutureWise Key Takeaways: Growth Prospects SWOT Analysis Key Trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global cardiac biomarker diagnostic kits market by type, by product, by disease, by type of testing and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities) To forecast and evaluate micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the rest of the world To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Factors such as increasing geriatric population and increasing cases of cardiovascular diseases are increasing the cardiac biomarker diagnostic kits market size. Current clinical trials for identification of novel cardiac biomarkers coupled with increasing fund from public-private organizations for research and development is also expanding the market.
The market is bifurcated into by type, by product, by disease, by type of testing and by region. The troponin I and T segment are expected to show notable cardiac biomarker diagnostic kits market growth owing to its high sensitivity, rapid prediction of outcomes and high specificity. It also offers longer elevation time. All these benefits have resulted in demand for troponin I and T, thus proliferating the market.
Based on product, reagents and kits are expected to dominate the growth of the market. Increasing cases of cardiovascular diseases and the availability of multiple reagents ad kits is driving the growth of the market. In addition, the continuous launch of reliable, faster and new reagents and kits increasing the cardiac biomarker diagnostic kits size.
On the basis of the type of testing, point-of-care testing is expected to control the growth of the market. Point-of-care testing offers various benefits such as enhanced user and patient experience, reduced length of stay and better turnaround times. All these benefits have resulted in rising point-of-care testing procedures. Technological advancements have led in much faster, advances and easy to use devices, thus resulting in expansion of the market.
In terms of disease, myocardial infarction segment is expected to control the growth of the market. The increasing number of patients required for the diagnosis of acute myocardial infarction remains the major factor boosting the growth of the market.
In terms of region, North America is the global front runner of the market. The rise in geriatric population coupled with presence of prominent players is bolstering the market in the region. The increasing incidence of cardiovascular disease coupled with rising adoption of point-of-care diagnostic is expected to accelerate the growth of the market in the region.
Prominent players of the market are BioMerieux SA, Guangzhou Wondfo Biotech Co., Ltd, Danaher Corporation, Siemens AG, Abbott Laboratories, Alere, Inc., LSI Medience Corporation, Randox laboratories, and Ortho Clinical Diagnostics.
Cardiac Biomarker Diagnostic Kits Market Segmentation:
By Product
By Type
By Type of Testing
By Disease
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Cardiac Biomarker Diagnostic Kits Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Cardiac Biomarker Diagnostic Kits Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Cardiac Biomarker Diagnostic Kits Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Cardiac Biomarker Diagnostic Kits Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Reagents and Kits 7.2. Instruments 7.3. Chemiluminescence 7.4. Immunofluorescence 7.5. Elisa 7.6. Immunochromatography 8. Cardiac Biomarker Diagnostic Kits Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Troponin I and T 8.2. CK-MB 8.3. Bnp Or Nt-Probnp 8.4. Myoglobin 8.5. Hscrp 8.6. Other Biomarkers 9. Cardiac Biomarker Diagnostic Kits Market, By Type of Testing Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Laboratory Testing 9.2. Point-Of-Care Testing 10. Cardiac Biomarker Diagnostic Kits Market, By Disease Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Myocardial Infarction 10.2. Congestive Heart Failure 11. North America Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. BioMerieux SA 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Guangzhou Wondfo Biotech Co., Ltd 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Danaher Corporation 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Siemens AG 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Abbott Laboratories 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Alere, Inc. 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. LSI Medience Corporation 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Randox laboratories 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Ortho Clinical Diagnostics 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Cardiac Biomarker Diagnostic Kits Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Cardiac Biomarker Diagnostic Kits Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Cardiac Biomarker Diagnostic Kits Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Cardiac Biomarker Diagnostic Kits Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Reagents and Kits 7.2. Instruments 7.3. Chemiluminescence 7.4. Immunofluorescence 7.5. Elisa 7.6. Immunochromatography
8. Cardiac Biomarker Diagnostic Kits Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Troponin I and T 8.2. CK-MB 8.3. Bnp Or Nt-Probnp 8.4. Myoglobin 8.5. Hscrp 8.6. Other Biomarkers
9. Cardiac Biomarker Diagnostic Kits Market, By Type of Testing Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Laboratory Testing 9.2. Point-Of-Care Testing
10. Cardiac Biomarker Diagnostic Kits Market, By Disease Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Myocardial Infarction 10.2. Congestive Heart Failure
11. North America Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Cardiac Biomarker Diagnostic Kits Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. BioMerieux SA 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Guangzhou Wondfo Biotech Co., Ltd 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Danaher Corporation 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Siemens AG 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Abbott Laboratories 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Alere, Inc. 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. LSI Medience Corporation 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Randox laboratories 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Ortho Clinical Diagnostics 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics